Verkalkungsneigung und kardiovaskuläres Risiko bei Dialysepatienten

ZUSAMMENFASSUNG

Dialysepatienten sind kardiovaskuläre Hochrisikopatienten. Mit Phosphat und Parathormon messen und behandeln wir heute lediglich 2 Faktoren des pathophysiologischen Verkalkungssystems. Als Kliniker sind wir bzgl. der Funktionalität dieses Verkalkungssystems weitgehend im Blindflug unterwegs. Wir behandeln zwar vermutlich das Richtige, können aber weder die Patientenprognose noch die Effektstärke unserer Interventionen gut abschätzen. Diese diagnostische Lücke könnte zukünftig der T50-Test füllen, ein neuartiger funktioneller Bluttest zur Messung der Verkalkungsneigung im Serum. Dieser Test hat das Potenzial, durch eine verbesserte koordinierte Therapielenkung und Einbeziehung etablierter Therapien ins Behandlungskonzept, zu einer Verbesserung des kardiovaskulären Outcomes von Dialysepatienten beizutragen.

Publication History

Article published online:
14 December 2021

• Literatur

• 1 Go AS, Chertow GM, Fan D. et al Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305 DOI: 10.1056/NEJMoa041031.
• 2 Kidney Disease: Improving Global Outcomes (KDIGO), CKD-MBD Update Work Group KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011) 2017; 7: 1-59 DOI: 10.1016/j.kisu.2017.04.001.
• 3 Ruospo M, Palmer SC, Natale P. et al Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev 2018; 8: CD006023 DOI: 10.1002/14651858.CD006023.pub3.
• 4 Palmer SC, Gardner S, Tonelli M. et al Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials. Am J Kidney Dis 2016; 68: 691-702 DOI: 10.1053/j.ajkd.2016.05.015.
• 5 EVOLVE Trial Investigators Chertow GM, Block GA. et al Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494 DOI: 10.1056/NEJMoa1205624.
• 6 Block GA, Raggi P, Bellasi A. et al Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441 DOI: 10.1038/sj.ki.5002059.
• 7 Schlieper G, Krüger T, Djuric Z. et al Vascular access calcification predicts mortality in hemodialysis patients. Kidney Int 2008; 74: 1582-1587 DOI: 10.1038/ki.2008.458.
• 8 Blacher J, Guerin AP, Pannier B. et al Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938-942 DOI: 10.1161/hy1001.096358.
• 9 Bäck M, Aranyi T, Cancela ML. et al Endogenous calcification inhibitors in the prevention of vascular calcification: a consensus statement from the COST Action EuroSoftCalcNet. Front Cardiovasc Med 2019; 5: 196 DOI: 10.3389/fcvm.2018.00196.
• 10 Heiss A, DuChesne A, Denecke B. et al Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003; 178: 13333-13341 DOI: 10.1074/jbc.M210868200.
• 11 Heiss A, Eckert T, Aretz A. et al Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles. J Biol Chem 2008; 283: 14815-14825 DOI: 10.1074/jbc.M709938200.
• 12 Ketteler M, Bongartz P, Westenfeld R. et al Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833 DOI: 10.1016/S0140-6736(03)12710-9.
• 13 Hamano T, Matsui I, Mikami S. et al Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 2010; 11: 199-2007 DOI: 10.1681/ASN.2009090944.
• 14 Smith ER, Ford ML, Tomlinson LA. et al Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant 2011; 27: 1957-1966 DOI: 10.1093/ndt/gfr609.
• 15 Smith ER, Cai MM, McMahon LP. et al Serum fetuin-A concentration and fetuin-A-containing calciprotein particles in patients with chronic inflammatory disease and renal failure. Nephrology (Carlton) 2013; 18: 215-221 DOI: 10.1111/nep.12021.
• 16 Herrmann M, Schafer C, Heiss A. et al Clearance of fetuin-A--containing calciprotein particles is mediated by scavenger receptor-A. Circ Res 2012; 111: 575-584 DOI: 10.1161/CIRCRESAHA.111.261479.
• 17 Bressendorff I, Hansen D, Pasch A. et al The effect of increasing dialysate magnesium on calciprotein particles, inflammation and bone markers: post hoc analysis from a randomized controlled clinical trial. In, Nephrol Dial Transplant 2021; 36: 713-721 DOI: 10.1093/ndt/gfz234.
• 18 Aghagolzadeh P, Bachtler M, Bijarnia R. et al Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-alpha. Atherosclerosis 2016; 251: 404-414 DOI: 10.1016/j.atherosclerosis.2016.05.044.
• 19 Pasch A, Jahnen-Dechent W, Smith ER. Phosphate, calcification in blood, and mineral stress: the physiologic blood mineral buffering system and its association with cardiovascular risk. Int J Nephrol 2018; 2018: 9182078 DOI: 10.1155/2018/9182078.
• 20 Pasch A, Farese S, Graber S. et al Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 2012; 23: 1744-1752 DOI: 10.1681/ASN.2012030240.
• 21 Pasch A, Bachtler Block GA. et al Blood calcification propensity, crdiovascular events, and survival in patients receiving hemodialysis in the EVOLVE trial. Clin J Am Soc Nephrol 2017; 12: 315-322 DOI: 10.2215/CJN.04720416.
• 22 Sanchez RR, Zawada A, Wolf M. et al P1433 Validation of a serum calcification propensity test for the prediction of all-cause mortality among dialysis patients. Nephrol Dial Transplant 2020; 35: iii270 DOI: 10.1093/ndt/gfaa144.P1433.
• 23 Smith ER, Ford ML, Tomlinson LA. et al Serum calcification propensity predicts all-cause mortality in predialysis CKD. J Am Soc Nephrol 2014; 25: 339-348 DOI: 10.1681/ASN.2013060635.
• 24 Bundy JD, Cai X, Mehta RC. et al Serum calcification propensity and clinical events in CKD. Clin J Am Soc Nephrol 2019; 14: 1562-1571 DOI: 10.2215/CJN.04710419.
• 25 Keyzer CA, de Borst MH, van den Berg E. et al Calcification propensity and survival among renal transplant recipients. J Am Soc Nephrol 2016; 27: 239-248 DOI: 10.1681/ASN.2014070670.
• 26 Dahle DO, Åsberg A, Hartmann A. et al Serum calcification propensity is a strong and independent determinant of cardiac and all-cause mortality in kidney transplant recipients. Am J Transplant 2016; 16: 204-212 DOI: 10.1111/ajt.13443.
• 27 Bostom A, Pasch A, Madsen T. et al Serum calcification propensity and fetuin-A: biomarkers of cardiovascular disease in kidney transplant recipients. Am J Nephrol 2018; 48: 21-31 DOI: 10.1159/000491025.
• 28 Eelderink C, Te Velde-Keyzer CA, Frenay AS. et al Serum calcification propensity and the risk of cardiovascular and all-cause mortality in the general population: the PREVEND study. Arterioscler Thromb Vasc Biol 2020; 40: 1942-1951 DOI: 10.1161/ATVBAHA.120.314187.
• 29 Ponte B, Pruijm M, Pasch A. et al Dialysis initiation improves calcification propensity. Nephrol Dial Transplant 2020; 35: 495-502 DOI: 10.1093/ndt/gfz222.
• 30 Dekker M, Pasch A, van der Sande F. et al High-flux hemodialysis and high-volume hemodiafiltration improve serum calcification propensity. PLoS One 2016; 4: e0151508 DOI: 10.1371/journal.pone.0151508.
• 31 Thiem U, Soellradl I, Robl B. et al The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial. Clin Kidney J 2020; 14: 631-638 DOI: 10.1093/ckj/sfaa154.
• 32 Ketteler M, Wiecek A, Rosenkranz AR. et al Efficacy and safety of a novel nicotinamide modified-release formulation in the treatment of refractory hyperphosphatemia in patients receiving hemodialysis – a randomized clinical trial. Kidney Int Rep 2020; 6: 594604 DOI: 10.1016/j.ekir.2020.12.012.
• 33 Bressendorff I, Hansen D, Schou M. et al The effect of increasing dialysate magnesium on serum calcification propensity in subjects with end stage kidney disease: a randomized, controlled clinical trial. Clin J Am Soc Nephrol 2018; 13: 1373-1380 DOI: 10.2215/CJN.13921217.
• 34 Ter Meulen KJ, Dekker MJE, Pasch A. et al Citric-acid dialysate improves the calcification propensity of hemodialysis patients: A multicenter prospective randomized cross-over trial. PLoS One 2019; 14: e0225824 DOI: 10.1371/journal.pone.0225824.
• 35 Lorenz G, Mayer CC, Bachmann Q. et al Acetate-free, citrate-acidified bicarbonate dialysis improves serum calcification propensity-a preliminary study. Nephrol Dial Transplant 2018; 33: 2043-2051 DOI: 10.1093/ndt/gfy134.
• 36 Shoji T, Nakatani S, Kabata D. et al Comparative effects of etelcalcetide and maxacalcitol on serum calcification propensity in secondary hyperparathyroidism: a randomized clinical trial. Clin J Am Soc Nephrol 2021; 16: 599-612 DOI: 10.2215/CJN.16601020.
• 37 Bressendorff I, Hansen D, Schou M. et al Oral magnesium supplementation in chronic kidney disease stages 3 and 4: efficacy, safety, and effect on serum calcification propensity –a prospective randomized double-blinded placebo-controlled clinical trial. Kidney Int Reports 2016; 2: 380-389 DOI: 10.1016/j.ekir.2016.12.008.
• 38 Cai MMX, Smith ER, Holt SG. The role of fetuin-A in mineral trafficking and deposition. Bonekey Rep 2015; 4: 672 DOI: 10.1038/bonekey.2015.39.